androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases-impact of AR-V7 expression on abiraterone, enzalutamide, and taxane therapy.
Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review / Sciarra, A., Gentilucci, A., Silvestri, I., Salciccia, S., Cattarino, S., Scarpa, S., Gatto, A., Frantellizzi, V., Von Heland, M., Ricciuti, G.P., Del Giudice, F., Maggi, M.. - In: MEDICINE. - ISSN 0025-7974. - 98:19(2019), pp. e15608-e15608. [10.1097/MD.0000000000015608]
Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
Sciarra, Alessandro
;Gentilucci, Alessandro;Silvestri, Ida;Salciccia, Stefano;Cattarino, Susanna;Scarpa, Susanna;Gatto, Antonio;Frantellizzi, Viviana;Von Heland, Magnus;Ricciuti, Gian Piero;Del Giudice, Francesco;Maggi, Martina
2019
Abstract
androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases-impact of AR-V7 expression on abiraterone, enzalutamide, and taxane therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sciarra_Androgen receptor_2019.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
496.36 kB
Formato
Adobe PDF
|
496.36 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
